Endothelial progenitor cells and their potential therapeutic applications

Regenerative Medicine

Volumn 3, Issue 6, 2008, Pages 863-876

  Khoo, Cheen P ^a,b   Pozzilli, Paolo ^a,b   Alison, Malcolm R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Bone marrow; Endothelial progenitor cells; Mobilization; Neoplasia; Neovasculogenesis; Peripheral blood; VEGF

Indexed keywords

ADRENOMEDULLIN; BEVACIZUMAB; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PLACENTAL GROWTH FACTOR; SIMVASTATIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; BREAST CANCER; CARCINOGENESIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL THERAPY; CLINICAL TRIAL; CORNEA INJURY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG MECHANISM; EMPHYSEMA; ENDOTHELIUM CELL; ENTERITIS; HEART MUSCLE ISCHEMIA; HEMATOPOIETIC STEM CELL; HUMAN; LIMB ISCHEMIA; LIVER CANCER; LIVER REGENERATION; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RECTUM CANCER; REVIEW; STEM CELL; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING; TISSUE REGENERATION; TREATMENT RESPONSE; VASCULAR DISEASE;

ANIMALS; CELL MOVEMENT; ENDOTHELIAL CELLS; HUMANS; NEOPLASMS; STEM CELL TRANSPLANTATION; STEM CELLS; TISSUE THERAPY;

EID: 58149114612     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460751.3.6.863     Document Type: Review

References (136)

1. Asahara T, Murohara T, Sullivan A et al.: Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964-967 (1997).
2. + endothelial precursor cells. Circ. Res. 88, 167-174 (2001).
3. Takahashi T, Kalca C, Masuda H et al.: Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat. Med. 5, 434-438 (1999).
4. Lyden D, Hattori K, Dias S et al.: Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7, 1194-1201 (2001).
5. Murohara T, Ikeda H, Duan J et al. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J. Clin. Invest. 105, 1527-1536 (2000).
6. + cells identifies a population of functional endothelial precursors. Blood 95, 952-958 (2000).
7. Majka SM, Jackson KA, Kienstra KA, Majesky MW, Goodell MA, Hirschi KK: Distinct progenitor populations in skeletal muscle are bone marrow derived and exhibit different cell fates during vascular regeneration. J. Clin. Invest. 111, 71-79 (2003).
8. Zammaretti P, Zisch AH. Adult endothelial progenitor cells'. Renewing vasculature. Int. J. Biocbem. Cell. Biol. 37, 493-503 (2005).
9. Rumpold H, Wolf D, Koeck R, Gunsilius E: Endothelial progenitor cells: a source for therapeutic vasculogenesis? J. Cell. Mol. Med. 8, 509-518 (2004).
10. Ziegler BL, Valtieri M, Porada GA et al.: KDR receptor: a key marker defining hematopoietic stem cells. Science 285, 1553-1558 (1999).
11. Haruta H, Nagata. Y, Todokoro K: Role of Flk-1 in mouse hematopoietic stem cells. FEBS Lett. 507, 45-48 (2001).
12. + progenitors share phenotypic, functional and gene expression profile similarities with lymphatics. J. Cell. Mol. Med. (2008) (Epub ahead of print).
13. McCloskey KE, Smith DA, Jo H, Nerem RM: Embryonic stem cell-derived endothelial cells may lack complete functional maturation in vitro. J. Vasc. Res. 43, 411-421 (2006).
14. Baldwin HS, Shen HM, Yan HC et al.: Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31); alternatively spliced, functionally distinct isoforms expressed during mammalian cardiovascular development. Development 120, 2539-2553 (1994).
15. Shaw JP, Basch R, Shamamian P: Hematopoietic stem cells and endothelial cell precursors express Tie-2, CD31 and CD45. Blood Cells Mol. Dis. 32, 168-175 (2004).
16. Rogers I, Yamanaka N, Bielecki R et al.: Identification and analysis of in vitro cultured CD45-positive cells capable of multi-lineage differentiation. Exp. Cell Res. 313, 1839-1852 (2007).
17. Puri MC, Bernstein A: Requirement for the TIE family of receptor tyrosine kinases in adult but not fetal hematopoiesis. Proc. Natl Acad. Sci. USA 100, 12753-12758 (2003).
18. Sato TN, Qin Y, Kozak CA, Audus KL: Tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system. Proc. Natl Acad. Sci. USA 90, 9355-9358 (1993).
19. Hsu HC, Ema H, Osawa M, Nakamura Y, Suda T, Nakauchi H: Hematopoietic stem cells express Tie-2 receptor in the murine fetal liver. Blood 96, 3757-3762 (2000).
20. Sato TN, Tozawa Y, Deutsch U et al.: Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376, 70-74 (1995).
21. Yin AH, Miraglia S, Zanjani ED et al.: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90, 5002-5012 (1997).
22. - hematopoietic stem cells using cell surface markers AC133 and CD7. Blood 95, 2813-2820 (2000).
23. + cells. Br. J. Haematol. 115, 186-194 (2001).
24. Kaushal S, Amiel GE, Guleserian KJ et al.: Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo. Nat. Med. 7, 1035-1040 (2001).
25. Simmons PJ, Aylett GW, Niutta S, To LB, Juttner CA, Ashman LK: c-kit is expressed by primitive human hematopoietic cells that give rise to colony-forming cells in stroma-dependent or cytokine-supplemented culture. Exp. Hematol. 22, 157-165 (1994).
26. Grant MB, May WS, Caballero S et al.: Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat. Med. 8, 607-612 (2002).
27. Spangrude GJ, Scollay R: A simplified method for enrichment of mouse hematopoietic stem cells. Exp. Hematol. 18, 920-926 (1990).
28. Solovey AN, Gui L, Chang L, Enenstein J, Browne PV, Hebbel RP: Identification and functional assessment of endothelial P1H12. J. Lab. Clin. Med. 138, 322-331 (2001).
29. Kaplan RN, Riba RD, Zacharoulis S et al.: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820-827 (2005).
30. Balasubramaniam V, Mervis CF, Maxey AM, Markham NE, Abman SH: Hyperoxia reduces bone marrow, circulating, and lung endothelial progenitor cells in the developing lung: implications for the pathogenesis of bronchopulmonary dysplasia. Am. J. Physiol. Lung Cell. Mol. Physiol. 292, L1073-1084 (2007).
31. Loomans CJ, Wan H, de Crom R et al.: Angiogenic murine endothelial progenitor cells are derived from a myeloid bone marrow fraction and can be identified by endothelial NO synthase expression. Arterioscler. Thromb. Vasc. Biol. 26, 1760-1767, (2006).
32. Sharpe EE 3rd, Teleron AA, Li B et al.: The origin and in vivo significance of murine and human culture-expanded endothelial progenitor cells. Am. J. Pathol. 168, 1710-1721 (2006).
33. Wang CH, Cherng WJ, Yang NI et al.: Cyclosporine increases ischemia-induced endothelial progenitor cell mobilization through manipulation of the CD26 system. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294, R811-818 (2008).
34. Hess D, Li L, Martin M et al.: Bone marrow-derived stem cells initiate pancreatic regeneration. Nat. Biotechnol. 21, 763-770 (2003).
35. Ye C, Bai L, Yan ZQ, Wang YH, Jiang ZL: Shear stress and vascular smooth muscle cells promote endothelial differentiation of endothelial progenitor cells via activation of Akt. Clin. Biomech. (2007) (Epub ahead of print).
36. Drake CJ, Fleming PA: Vasculogenesis in the day 6.5 to 9.5 mouse embryo. Blood 95, 1671-1679 (2000).
37. Wang QR, Wang BH, Huang YH, Dai G, Li WM, Yan Q: Purification and growth of endothelial progenitor cells from murine bone marrow mononuclear cells. J. Cell. Biochem. 103, 21-29 (2008).
38. +) for therapeutic vasculogenesis in a patient with critical limb ischemia. One year follow-up. Cytotherapy 9, 99-102 (2007).
39. Igreja C, Fragoso R, Caiado F et al.: Detailed molecular characterization of cord blood-derived endothelial progenitors. Exp. Hematol. 36, 193-203 (2008).
40. Matsumoto T, Mifune Y, Kawamoto A et al.: Fracture induced mobilization and incorporation of bone marrow-derived endothelial progenitor cells for bone healing. J. Cell. Physiol. 215, 234-242 (2008).
41. + cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp. Hematol. 35, 1109-1118 (2007).
42. Hur J, Yoon CH, Kim HS et al.: Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler. Thromb. Vasc. Biol. 24, 288-293 (2004).
43. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP: Origins of circulating endothelial cells and endothelial outgrowth from blood. J. Clin. Invest. 105, 71-77 (2000).
44. Kalka C, Masuda H, Takahashi T et al.: Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc. Natl Acad. Sci. USA 97, 3422-3427 (2000).
45. Mukai N, Akahori T, Komaki M et al.: A comparison of the tube forming potentials of early and late endothelial progenitor cells. Exp. Cell Res. 314, 430-440 (2008).
46. Akita T, Murohara T, Ikeda H et al.: Hypoxic preconditioning augments efficacy of human endothelial progenitor cells for therapeutic neovascularization. Lab. Invest. 83, 65-73 (2003).
47. Mizrak D, Brittan M, Alison MR: CD133: molecule of the moment. J. Pathol. 214, 3-9 (2008).
48. Fadini GP, Baesso I, Albiero M, Sartore S, Agostini C, Avogaro A: Technical notes on endothelial progenitor cells: ways to escape from the knowledge plateau. Atherosclerosis 197, 496-503 (2008).
49. + progenitors share phenotypic, functional and gene expression profile similarities with lymphatics. J. Cell. Mol. Med. (2008) (Epub ahead of print).
50. Shantsila E, Watson T, Tse HF, Lip GY: New insights on endothelial progenitor cell subpopulations and their angiogenic properties. J. Am. Coll. Cardiol. 51, 669-671 (2008).
51. Yamamoto H, Kato H, Uruma M, Nitta M, Takamoto S: Identification of two distinct populations of endothelial progenitor cells differing in size and antigen expression from human umbilical cord blood. Ann. Hematol. 87, 87-95 (2008).
52. Bischoff J, Brasel C, Kraling B, Vranovska K: E-selectin is upregulated in proliferating endothelial cells in vitro. Microcirculation 4, 279-287 (1997).
53. Kraling BM, Razon MJ, Boon LM et al.: E-selectin is present in proliferating endothelial cells in human hemangiomas. Am. J. Pathol. 148, 1181-1191 (1996).
54. Nishiwaki Y, Yoshida M, Iwaguro H et al.: Endothelial E-selectin potentiates neovascularization via endothelial progenitor cell-dependent and -independent mechanisms. Arterioscler. Thromb. Vasc. Biol. 27, 512-518 (2007).
55. Mathews V, Hanson PT, Ford E, Fujita J, Polonsky KS, Graubert TA: Recruitment of bone marrow-derived endothelial cells to sites of pancreatic beta-cell injury. Diabetes 53, 91-98 (2004).
56. Asahara T, Takahashi T, Masuda H et al.: VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 18, 3964-3972 (1999).
57. Heissig B, Hattori K, Dias S et al.: Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 109, 625-637 (2002).
58. Rafii S, Meeus S, Dias S et al.: Contribution of marrow-derived progenitors to vascular and cardiac regeneration. Semin. Cell. Dev. Biol. 13, 61-67 (2002).
59. Aicher A, Zeiher AM, Dimmeler S: Mobilizing endothelial progenitor cells. Hypertension 45, 321-325 (2005).
60. Aicher A, Heeschen C, Mildner-Rihm C et al.: Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat. Med. 9, 1370-1376 (2003).
61. Brem H, Tomic-Canic M: Cellular and molecular basis of wound healing in diabetes. J. Clin. Invest. 117, 1219-1222 (2007).
62. Kucia M, Jankowski K, Reca R et al.: CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J. Mol. Histol. 35, 233-245 (2004).
63. Gallagher KA, Liu ZJ, Xiao M et al.: Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1α. J. Clin. Invest. 117, 1249-1259 (2007).
64. Heeschen C, Aicher A, Lehmann R et al.: Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102, 1340-1346 (2003).
65. Ishizawa K, Kubo H, Yamada M et al.: Bone marrow-derived cells contribute to lung regeneration after elastase-induced pulmonary emphysema. FEBS Lett. 556, 249-252 (2004).
66. Tamarat R, Silvestre JS, Le Ricousse-Roussanne S et al.: Impairment in ischemia-induced neovascularization in diabetes: bone marrow mononuclear cell dysfunction and therapeutic potential of placenta growth factor treatment. Am. J. Pathol. 164, 457-466 (2004).
67. Darland DC, D'Amore PA: Blood vessel maturation: vascular development comes of age. J. Clin. Invest. 103, 157-158 (1999).
68. Au P, Tam J, Fukumura D, Jain RK: Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. Blood 111, 4551-4558 (2008).
69. Melero-Martin JM, De Obaldia ME, Kang SY et al.: Engineering robust and functional vascular networks in vivo with human adult and cord blood-derived progenitor cells. Circ. Res. 103, 194-202 (2008).
70. Kocher AA, Schuster MD, Szabolcs MJ et al.: Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat. Med. 7, 430-436 (2001).
71. Losordo DW, Vale PR, Symes JF et al.: Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98, 2800-2804 (1998).
72. Rafii S, Lyden D: Cancer. A few to flip the angiogenic switch. Science 319, 163-164 (2008).
73. Moreno PR, Purushothaman KR, Fuster V et al.: Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 110, 2032-2038 (2004).
74. Tepper OM, Galiano RD, Capla JM et al.: Human endothelial progenitor cells from Type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 106, 2781-2786 (2002).
75. Landmesser U, Drexler H: The clinical significance of endothelial dysfunction. Curr. Opin. Cardiol. 20, 547-551 (2005).
76. Vagnucci AH Jr, Li WW: Alzheimer's disease and angiogenesis. Lancet 361, 605-608 (2003).
77. Iwaguro H, Yamaguchi J, Kalka C et al.: Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation 105, 732-738 (2002).
78. Schratzberger P, Walter DH, Rittig K et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J. Clin. Invest. 107, 1083-1092 (2001).
79. Hiasa K, Ishibashi M, Ohtani K et al.: Gene transfer of stromal cell-derived factor-1α enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization. Circulation 109, 2454-2461 (2004).
80. Llevadot J, Murasawa S, Kureishi Y et al.: HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J. Clin. Invest. 108, 399-405 (2001).
81. Kong D, Melo LG, Mangi AA et al.: Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation 109, 1769-1775 (2004).
82. Follenzi A, Benten D, Novikoff P, Faulkner L, Raut S, Gupta S: Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice. J. Clin. Invest. 118, 935-945 (2008).
83. Qiu HY, Fujimori Y, Nishioka K et al.: Postnatal neovascularization by endothelial progenitor cells immortalized with the simian virus 40T antigen gene. Int. J. Oncol. 28, 815-821 (2006).
84. + bone marrow cells. Blood 95, 581-585 (2000).
85. Nagano M, Yamashita T, Hamada H et al.: Identification of functional endothelial progenitor cells suitable for the treatment of ischemic tissue using human umbilical cord blood. Blood 110, 151-160 (2007).
86. Zhao X, Huang L, Yin Y, Fang Y, Zhou Y: Autologous endothelial progenitor cells transplantation promoting endothelial recovery in mice. Transpl. Int. 20, 712-721 (2007).
87. Ueno T, Nakamura T, Torimura T, Sata M: Angiogenic cell therapy for hepatic fibrosis. Med. Mol. Morphol. 39, 16-21 (2006).
88. Taniguchi E, Kin M, Torimura T et al.: Endothelial progenitor cell transplantation improves the survival following liver injury in mice. Gastroenterology 130, 521-531 (2006).
89. Murasawa S, Llevadot J, Silver M, Isner JM, Losordo DW, Asahara T: Constitutive human telomerase reverse transcriptase expression enhances regenerative properties of endothelial progenitor cells. Circulation 106, 1133-1139 (2002).
90. Dome B, Timar J, Dobos J et al.: Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res. 66, 7341-7347 (2006).
91. Schmidt-Lucke C, Rossig L, Fichtlscherer S et al.: Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 111, 2981-2987 (2005).
92. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA: Vascular endothelial growth factor and angiogenesis. Pharmacol. Rev. 56, 549-580 (2004).
93. Kawamoto A, Asahara T, Losordo DW: Transplantation of endothelial progenitor cells for therapeutic neovascularization. Cardiovasc. Radiat. Med. 3, 221-225 (2002).
94. Assmus B, Schachinger V, Teupe C et al.: Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 106, 3009-3017 (2002).
95. Schachinger V, Assmus B, Honold J et al.: Normalization of coronary blood flow in the infarct-related artery after intracoronary progenitor cell therapy: intracoronary Doppler substudy of the TOPCARE-AMI trial. Clin. Res. Cardiol. 95, 13-22 (2006).
96. Ellis SG, Penn MS, Bolwell B et al.: Granulocyte colony stimulating factor in patients with large acute myocardial infarction: results of a pilot dose-escalation randomized trial. Am. Heart J. 152, 1051 e1059-1014 (2006).
97. Zohlnhofer D, Kastrati A, Schomig A: Stem cell mobilization by granulocyte-colony-stimulating factor in acute myocardial infarction: lessons from the REVIVAL-2 trial. Nat. Clin. Pract. Cardiovasc. Med. 4(Suppl. 1), S106-S109 (2007).
98. Takahashi M, Nakamura T, Toba T, Kajiwara N, Kato H, Shimizu Y: Transplantation of endothelial progenitor cells into the lung to alleviate pulmonary hypertension in dogs. Tissue Eng. 10, 771-779 (2004).
99. Nagaya N, Kangawa K, Kanda M et al.: Hybrid cell-gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells. Circulation 108, 889-895 (2003).
100. Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, Stewart DJ: Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ. Res. 96, 442-450 (2005).
101. Loomans CJ, De Koning EJ, Staal FJ, Rabelink TJ, Zonneveld AJ: Endothelial progenitor cell dysfunction in Type 1 diabetes: another consequence of oxidative stress? Antioxid. Redox Signal. 7, 1468-1475 (2005).
102. Shapiro AM, Lakey JR, Ryan EA et al.: Islet transplantation in seven patients with Type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343, 230-238 (2000).
103. Hasegawa Y, Ogihara T, Yamada T et al.: Bone marrow (BM) transplantation promotes β-cell regeneration after acute injury-through BM cell mobilization. Endocrinology 148, 2006-2015 (2007).
104. Nikolova G, Jabs N, Konstantinova I et al.: The vascular basement membrane: a niche for insulin gene expression and β cell proliferation. Dev. Cell 10, 397-405 (2006).
105. Fujii H, Hirose T, Oe S et al.: Contribution of bone marrow cells to liver regeneration after partial hepatectomy in mice. J. Hepatol. 36, 653-659 (2002).
106. Kienstra KA, Jackson KA, Hirschi KK: Injury mechanism dictates contribution of bone marrow-derived cells to murine hepatic vascular regeneration. Pediatr. Res. 63, 131-136 (2008).
107. Alison MR, Choong C, Lim S: Application of liver stem cells for cell therapy. Semin. Cell. Dev. Biol. 18, 819-826 (2007).
108. Yannaki E, Anagnostopoulos A, Kapetanos D et al.: Lasting amelioration in the clinical course of decompensated alcoholic cirrhosis with boost infusions of mobilized peripheral blood stem cells. Exp. Hematol. 34, 1583-1587 (2006).
109. Brittan M, Chance V, Elia G et al.: A regenerative role for bone marrow following experimental colitis: contribution to neovasculogenesis and myofibroblasts. Gastroenterology 128, 1984-1995 (2005).
110. Oyama Y, Craig RM, Traynor AE et al.: Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology 128, 552-563 (2005).
111. Hill JM, Zalos G, Halcox JP et al.: Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med. 348, 593-600 (2003).
112. Hink U, Li H, Mollnau H et al.: Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ. Res. 88, E14-22 (2001).
113. Loomans CJ, de Koning EJ, Staal FJ et al.: Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of Type 1 diabetes. Diabetes 53, 195-199 (2004).
114. Garber AJ: Vascular disease and lipids in diabetes. Med. Clin. North Am. 82, 931-948 (1998).
115. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339, 229-234 (1998).
116. Kunz GA, Liang G, Cuculi F et al.: Circulating endothelial progenitor cells predict coronary artery disease severity. Am. Heart J. 152, 190-195 (2006).
117. Werner N, Kosiol S, Schiegl T et al.: Circulating endothelial progenitor cells and cardiovascular outcomes. N. Engl. J. Med. 353, 999-1007 (2005).
118. Choi JH, Kim KL, Huh W et al.: Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler. Thromb. Vasc. Biol. 24, 1246-1252 (2004).
119. Chen JZ, Zhang FR, Tao QM, Wang XX, Zhu JH, Zhu JH: Number and activity of endothelial progenitor cells from peripheral blood in patients with hypercholesterolaemia. Clin. Sci. (Lond.) 107, 273-280 (2004).
120. Spring H, Schuler T, Arnold B, Hammerling GJ, Ganss R: Chemokines direct endothelial progenitors into tumor neovessels. Proc. Natl Acad. Sci. USA 102, 18111-18116 (2005).
121. Hilbe W, Dirnhofer S, Oberwasserlechner F et al.: CD133 positive endothelial progenitor cells contribute to the tumor vasculature in non-small cell lung cancer. J. Clin. Pathol. 57, 965-969 (2004).
122. Natori T, Sata M, Washida M, Hirata Y, Nagai R, Makuuchi M: G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells. Biochem. Biophys. Res. Commun. 297, 1058-1061 (2002).
123. Hammerling GJ, Ganss R: Vascular integration of endothelial progenitors during multistep tumor progression. Cell Cycle 5, 509-511 (2006).
124. Larrivee B, Niessen K, Pollet I et al.: Minimal contribution of marrow-derived endothelial precursors to tumor vasculature. J. Immunol. 175, 2890-2899 (2005).
125. + stem cells do not contribute to vasculogenesis in Lewis lung carcinoma. Neoplasia 7, 234-240 (2005).
126. Dwenger A, Rosenthal F, Machein M, Waller C, Spyridonidis A: Transplanted bone marrow cells preferentially home to the vessels of in situ generated murine tumors rather than of normal organs. Stem Cells 22, 86-92 (2004).
127. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V: Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319, 195-198 (2008).
128. Purhonen S, Palm J, Rossi D et al.: Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc. Natl Acad. Sci. USA 105, 6620-6625 (2008).
129. Kerbel RS, Benezra R, Lyden DC et al.: Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas. Proc. Natl Acad. Sci. USA 105, E54; author reply E55 (2008).
130. Peters BA, Diaz LA, Polyak K et al.: Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat. Med. 11, 261-262 (2005).
131. Ho JW, Pang RW, Lau C et al.: Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology 44, 836-843 (2006).
132. Lin EH, Hassan M, Li Y et al.: Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence. Cancer 110, 534-542 (2007).
133. Bertolini F, Paul S, Mancuso P et al.: Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 63, 4342-4346 (2003).
134. Willett CG, Boucher Y, di Tomaso E et al.: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10, 145-147 (2004).
135. Shaked Y, Bocci G, Munoz R et al.: Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose. Curr. Cancer Drug Targets 5, 551-559 (2005).
136. Naik RP, Jin D, Chuang E et al.: Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer. Breast Cancer Res. Treat. 107, 133-138 (2008).